Login
Home / SMDPY : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sumitomo Pharma Co., Ltd.

$10.45 -$1.00 (-8.73%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$10.45
Day Range
$10.45$11
Year Range
$7.84$24.48
Market Cap
4.69B
AVG Volume
933
Trailing/Forward PE
5.44/-
PEG ratio
2.06
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (JPY)
050B100B150B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Net Income (JPY)
-200B-100B0100B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Operating Income (JPY)
-300B-200B-100B0100B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
EBITDA (JPY)
-300B-200B-100B0100B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Cash Flows (JPY)
-40B-20B020B40B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
EPS (JPY)
-600-400-200020040024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Expenses (JPY)
0100B200B300BR&DSG&ACapex24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Cash & Debt (JPY)
0200B400B600BCashLong Term DebtShort Term Debt24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Debt ratios
-2.502.557.524 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Margins
0%20%40%60%80%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Return on Capital
-150%-100%-50%0%50%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Shares Outstanding
0200M400M600M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Dividends (JPY)
00.511.5Mar 23
Book Value Per Share (JPY)
0250500750100024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Total Assets (JPY)
0250B500B750B1T24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
PE Ratio
010203040med 6.91Jan 23Jul 25Oct 25Jan 26Mar 26Jun 26Sep 26
Free Cash Flow Yield
-300%-200%-100%0%100%med 2.2%Sep 24Jan 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Sales
0123med 1.3Sep 24Jan 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
0102030med 6.42Feb 23May 23Aug 25Nov 25Feb 26Jun 26Sep 26
Price/Operating Cashflow
010203040med 13.42Feb 23May 23Aug 25Nov 25Feb 26Jun 26Sep 26
Price to Book
012345med 2.25Sep 24Jan 25Jul 25Oct 25Feb 26May 26Sep 26
Sumitomo Pharma Co., Ltd.
SMDPY
Stockpicker

Video analysis: SMDPY

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SMDPY

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

businesswire.com · 12 Aug 2026

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells. This Phase 1/2a, open-label, single-arm, uncontrolled, dose-escalation study (NCT06891885) is evaluating tw.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.